Overall rank by patents
#43,141
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Serimmune Inc.
USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
6
Total patents granted
6
CPC technology areas
28.8
Avg claims per patent
+400%
5-year filing velocity
The verdict
Serimmune holds 6 US patents across 6 technology areas, rank #43,141 of 50,000 tracked assignees.
- #43,141
- of 50,000 US assignees by volume
- Top 45%
- by Innovation Score (37.0/100)
- 28.8
- avg claims per patent
- +400%
- filing velocity, last 5 yrs
Portfolio overview
Serimmune Inc. has been granted 6 US utility patents between 2019 and 2025, placing Serimmune Inc. at rank #43,141 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 28.8 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Serimmune Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Serimmune sits between Sentek Pty Ltd. (6 patents, rank #43,137) and Setaysha Technical Solutions Llc (6 patents, rank #43,145) - the closest US assignees by grant volume. The composite Innovation Score of 37.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 1 in the 2015–2019 window, a +400% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Serimmune Inc.'s 28.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Serimmune Inc. against peers pursuing similar technology classes.
Who files at Serimmune's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Sentek Pty
Sentek Pty Ltd.
6 patents
- Sentient Science
Sentient Science Corporation
6 patents
- Sentry Protection
Sentry Protection LLC
6 patents
- Sequoia Benefits…
Sequoia Benefits And Insurance Services, LLC
6 patents
- Sernova
Sernova Corporation
6 patents
- Service Managemen…
Service Management Group, LLC
6 patents
- Servosity
Servosity, Inc.
6 patents
- Setaysha Technica…
Setaysha Technical Solutions LLC
6 patents
- Serimmune ◀
Serimmune Inc.
6 patents
What this shows Serimmune holds 6 patents at rank #43,141, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Serimmune
By rank, the assignees closest to #43,141 in granted patent volume.
- Sentek Pty Ltd. #43,137 · 6 patents
- Sentient Science Corporation #43,138 · 6 patents
- Sentry Protection Llc #43,139 · 6 patents
- Sequoia Benefits And Insurance Services, Llc #43,140 · 6 patents
- Sernova Corporation #43,142 · 6 patents
- Service Management Group, Llc #43,143 · 6 patents
- Servosity, Inc. #43,144 · 6 patents
- Setaysha Technical Solutions Llc #43,145 · 6 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Serimmune's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
Serimmune's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
37 Top 45% higher than 55% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 16.7% |
| 2020 | 1 | 16.7% |
| 2023 | 1 | 16.7% |
| 2024 | 1 | 16.7% |
| 2025 | 2 | 33.3% |
Which technologies does Serimmune Inc. patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does Serimmune Inc. hold?
Serimmune Inc. holds 6 US granted patents filed between 2019 and 2025, spanning 6 technology areas.
What is Serimmune Inc.'s Innovation Score?
Serimmune Inc. has an Innovation Score of 37.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Serimmune Inc. focus on?
Serimmune Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 6 patents. The company has filed patents in 6 CPC subclasses total.
Is Serimmune Inc.'s patent filing rate increasing or decreasing?
Serimmune Inc.'s recent filing velocity is +400% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Serimmune Inc.'s patents?
Serimmune Inc.'s patents average 28.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Serimmune Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Serimmune's 6 grants land it in the top 45% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Serimmune ranks #43,141 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.